| Literature DB >> 30096866 |
Chia-Hua Wu1, Chih-Hua Chao2,3, Tzu-Zin Huang4, Chiung-Yao Huang5, Tsong-Long Hwang6,7,8, Chang-Feng Dai9, Jyh-Horng Sheu10,11,12,13.
Abstract
Five new cembranoid-related diterpenoids, namely, flexibilisins D and E (1 and 2), secoflexibilisolides A and B (3 and 4), and flexibilisolide H (5), along with nine known compounds (6⁻14), were isolated from the soft coral Sinularia flexibilis. Their structures were established by extensive spectral analysis. Compound 3 possesses an unusual skeleton that could be biogenetically derived from cembranoids. The cytotoxicity and anti-inflammatory activities of the isolates were investigated, and the results showed that dehydrosinulariolide (7) and 11-epi-sinulariolide acetate (8) exhibited cytotoxicity toward a limited panel of cancer cell lines and 14-deoxycrassin (9) displayed anti-inflammatory activity by inhibition of superoxide anion generation and elastase release in N-formyl-methionyl-leucyl-phenylalanine/cytochalasin B (fMLF/CB)-induced human neutrophils.Entities:
Keywords: Sinularia flexibilis; cembranoid-related compounds; flexibilisin; flexibilisolide; secoflexibilisolide
Mesh:
Substances:
Year: 2018 PMID: 30096866 PMCID: PMC6117644 DOI: 10.3390/md16080278
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of 1–5.
Figure 2Structures of metabolites 6−14.
1H and 13C NMR spectroscopic data of 1 and 2.
| Position | 1 | 2 | ||
|---|---|---|---|---|
| 1 | 2.85, m | 35.2 (CH) | 2.79, m | 36.5 (CH) |
| 2 | 2.05, m; 1.36, m | 31.5 (CH2) | 1.98, m; 1.40, m | 32.5 (CH2) |
| 3 | 2.81, dd (10.0, 4.0) | 60.1 (CH) | 2.77, dd; (9.6, 4.4) | 59.4 (CH) |
| 4 | 60.2 (C) | 60.7 (C) | ||
| 5 | 2.00, m; 1.59, m | 36.9 (CH2) | 1.99, m; 1.54, m | 36.8 (CH2) |
| 6 | 2.12, m; 2.08, m | 22.2 (CH2) | 2.10, m; 2.00, m | 22.9 (CH2) |
| 7 | 5.18, t (5.6) | 126.5 (CH) | 5.11, t (5.2) | 126.4 (CH) |
| 8 | 134.2 (C) | 134.6 (C) | ||
| 9 | 2.26, m; 2.09, m | 36.0 (CH2) | 2.55, m, 2.22, m | 31.6 (CH2) |
| 10 | 2.09, m; 1.40, m | 24.6 (CH2 | 2.71, ddd (10.8, 8.0, 2.8) | 34.3 (CH2) |
| 2.65, ddd (10.8, 8.0, 2.8) | ||||
| 11 | 2.65, dd (10.0, 3.2) | 61.9 (CH) | 213.6 (C) | |
| 12 | 60.8 (C) | 78.8 (C) | ||
| 13 | 1.70, m; 1.20, m | 33.0 (CH2) | 1.74, ddd (12.8, 5.6. 2.0) | 36.1 (CH2) |
| 14 | 1.70, m; 1.58, m | 27.4 (CH2) | 1.54, m, 1.37, m | 25.2 (CH2) |
| 15 | 142.7 (C) | 142.2 (C) | ||
| 16 | 167.3 (C) | 167.4 (C) | ||
| 17 | 6.26, s; 5.48, s | 124.4 (CH2) | 6.31, s, 5.49, s | 124.4 (CH2) |
| 18 | 1.29, s | 17.8 (CH3) | 1.27, s | 18.2 (CH3) |
| 19 | 1.65, s | 15.3 (CH3) | 1.66, s | 17.1 (CH3) |
| 20 | 1.23, s | 17.0 (CH3) | 1.34, s | 25.7 (CH3) |
| 16-OMe | 3.76, s | 52.0 (CH3) | 3.76, s | 52.0 (CH3) |
a Spectra recorded at 400 MHz in CDCl3. b Spectra recorded at 100 MHz in CDCl3. c J values (in Hz) in parentheses. d Attached protons were deduced by DEPT experiments.
Figure 3Key COSY and HMBC correlations for 1 and 2.
Figure 4Selective NOESY correlations for 1 and 5.
Figure 5Key COSY and HMBC correlations and selective NOESY correlations for 3.
Scheme 1Proposed biosynthetic pathway for 3.
1H, 13C NMR data, COSY, and HMBC correlations of 3.
| Position | COSY | HMBC | ||
|---|---|---|---|---|
| 1 | 2.13, m | 34.5 (CH) | H-2, 14 | C-3, 16 |
| 2 | 1.78, m; 1.38, m | 30.7 (CH2) | H-1, 3 | C-1, 3, 14, 15 |
| 3 | 2.74, dd (7.5, 6.5) | 61.9 (CH) | H-2 | C-2 |
| 4 | 58.8 (C) | |||
| 5 | 2.44, d (7.5) | 41.2 (CH2) | H-6 | C-3, 4, 6, 7, 18 |
| 6 | 6.73, m | 142.2 (CH) | H-5, 7 | C-4, 5, 7, 8 |
| 7 | 6.12, d (16.0) | 134.0 (CH) | H-6 | C-8 |
| 8 | 198.3 (C) | |||
| 9 | 1.82, m | 20.8 (CH2) | H-10, 17 | C-15 |
| 10 | 2.05, m; 1.68, m | 34.1 (CH2) | H-9 | C-9, 11, 12 |
| 11 | 85.3 (C) | |||
| 12 | 84.7 (C) | |||
| 13 | 2.10, m; 1.72, m | 30.4 (CH2) | C-11, 12 | |
| 14 | 1.96, m; 1.22, m | 25.8 (CH2) | C-12, 15 | |
| 15 | 60.9 (C) | |||
| 16 | 177.6 (C) | |||
| 17 | 2.26, m; 1.66, m | 28.4 (CH2) | H-9 | C-1, 15, 16 |
| 18 | 1.28, s | 17.2 (CH3) | C-3, 4, 5 | |
| 19 | 2.26, s | 27.0 (CH3) | C-7, 8 | |
| 20 | 1.39, s | 18.7 (CH3) | C-11, 12, 13 |
a Spectra recorded at 500 MHz in CDCl3. b Spectra recorded at 125 MHz in CDCl3. c J values (in Hz) in parentheses. d Attached protons were deduced by DEPT experiments.
1H and 13C NMR data of compounds 4 and 5.
| Position | 4 | 5 | ||
|---|---|---|---|---|
| 1 | 2.02, m | 35.9 (CH) | 2.92, m | 34.6 (CH) |
| 2 | 1.07, m; 1.02, m | 28.2 (CH2) | 2.14, m; 1.48, m | 33.3 (CH2) |
| 3 | 3.64, dd (11.6) | 83.0 (CH) | 3.07, dd (10.0, 4.0) | 61.7 (CH) |
| 4 | 72.5 (C) | 59.6 (C) | ||
| 5 | 2.14, m; 1.97, m | 41.3 (CH2) | 2.12, m; 1.48, m | 34.3 (CH2) |
| 6 | 5.66, m | 124.1 (CH) | 1.94, m; 1.91, m | 25.5 (CH2) |
| 7 | 5.20, dd (15.6, 6.8) | 136.9 (CH) | 4.53, d (10.0) | 81.2 (CH) |
| 8 | 83.9 (C) | 145.8 (C) | ||
| 9 | 1.44, m; 1.22, m | 33.9 (CH2) | 2.59, m; 2.23, m | 29.7 (CH2) |
| 10 | 2.05, m; 1.94, m | 28.7 (CH2) | 1.89, m; 1.78, m | 26.5 (CH2) |
| 11 | 175.4 (C) | 5.60, dd (12.8, 2.4) | 72.9 (CH) | |
| 12 | 205.6 (C) | 87.1 (C) | ||
| 13 | 1.76, m; 1.68, m | 39.4 (CH2) | 2.03, m; 1.92, m | 32.8 (CH2) |
| 14 | 1.62, m; 1.32, m | 28.0 (CH2) | 2.23, m; 1.38, m | 30.1 (CH2) |
| 15 | 139.5 (C) | 143.4 (C) | ||
| 16 | 165.3 (C) | 168.1 (C) | ||
| 17 | 6.40, s; 5.12, s | 126.0 (CH2) | 6.30, s; 5.50, s | 125.0 (CH2) |
| 18 | 1.00 s | 22.4 (CH3) | 1.40 s | 24.0 (CH3) |
| 19 | 1.04 s | 26.3 (CH3) | 5.09 s; 5.06 s | 115.0 (CH2) |
| 20 | 1.64 s | 29.4 (CH3) | 1.38 s | 15.5 (CH3) |
| OAc | 2.09 s | 20.9 (CH3) | ||
| 170.6 (C) | ||||
a Spectra recorded at 400 MHz in C6D6. b Spectra recorded at 100 MHz in C6D6. c Spectra recorded at 400 MHz in CDCl3. d Spectra recorded at 100 MHz in CDCl3. e J values (in Hz) in parentheses. f Attached protons were deduced by DEPT experiments.
Figure 6Key COSY and HMBC correlations for 4.
Scheme 2Proposed biosynthetic pathway for 4.
The cytotoxic activity of 7–9 and 11 a.
| Compound | IC50 (μM) | ||
|---|---|---|---|
| P-388 b | K-562 c | HT-29 d | |
| 9.3 | 23.4 | 15.9 | |
| 6.9 | 12.2 | 9.6 | |
| 16.0 | 26.7 | (–) | |
| (–) e | 21.7 | 27.1 | |
| Doxorubicin hydrochloride f | 0.3 | 1.0 | 0.9 |
a Compounds 1, 2, 4–6, 10, and 12–14 were inactive toward the three cancer cell lines with IC50 > 40 μM. b P-388: murine leukemia. c K-562: human erythromyeloblastoid leukemia. d HT-29: human colon adenocarcinoma. e (–): IC50 > 40 μM. f Positive control.